You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Type-specific prevalence of oncogenic HPV infection in women with histologically-confirmed CIN 2/3

From: Pre-vaccination type-specific HPV prevalence in confirmed cervical high grade lesions in the Māori and non-Māori populations in New Zealand

  CIN2/3 combined (N = 418)
  Māori (N=149) Non-Māori (N=269) Overall (N=418)
HR HPV type N % 95 % CI N % 95 % CI N % 95 % CI
HPV16 (any) 81 54 (46–63) 146 54 (48–60) 227 54 (49–59)
HPV52 (any) 22 15 (10–21) 53 20 (15–25) 75 18 (14–22)
HPV31 (any) 19 13 (8–19) 52 19 (15–25) 71 17 (14–21)
HPV33 (any) 15 10 (6–16) 38 14 (10–19) 53 13 (10–16)
HPV18 (any) 17 11 (7–18) 29 11 (7–15) 46 11 (8–14)
HPV58 (any) 16 11 (6–17) 36 13 (10–18) 52 12 (9–16)
HPV51 (any) 15 10 (6–16) 26 10 (6–14) 41 10 (7–13)
HPV39 (any) 12 8 (4–14) 19 7 (4–11) 31 7 (5–10)
HPV45 (any) 6 4 (2–9) 13 5 (3–8) 19 5 (3–7)
HPV59 (any) 9 6 (3–11) 13 5 (3–8) 22 5 (3–8)
HPV35 (any) 6 4 (2–9) 11 4 (2–7) 17 4 (2–6)
HPV56 (any) 8 5 (2–10) 4 2 (0–4) 12 3 (2–5)
HPV68 (any) 1 1 (0–4) 9 3 (2–6) 10 2 (1–4)
HPV16 and/or 18 (any) 92 62 (53–70) 167 62 (56–68) 259 62 (57–67)
 HPV16 with HPV18 (any) 6 4 (2–9) 7 3 (1–5) 13 3 (2–5)
 HPV16 without HPV18 (any) 75 50 (42–59) 139 52 (46–58) 214 51 (46–56)
 HPV18 without HPV16 (any) 11 7 (4–13) 21 8 (5–12) 32 8 (5–11)
HPV16 and/or 18 (without OHR) 56 38 (30–46) 72 27 (22–32) 128 31 (26–35)
HPV16 and/or 18 (with OHR) 36 24 (18–32) 95 35 (30–41) 131 31 (27–36)
OHR without HPV 16/18 51 34 (27–42) 92 34 (29–40) 143 34 (30–39)
HR HPV (single infection) 85 57 (49–65) 123 46 (40–52) 208 50 (45–55)
HR HPV (any) 143 96 (91–99) 258 96 (93–98) 401 96 (94–98)
HPV positive (including LR HPV) 143 96 (91–99) 261 97 (94–99) 404 97 (94–98)
  1. HR high risk, LR low risk, OHR Other high risk, excluding HPV 16 or 18; any – regardless of co-infection with other HPV types
  2. HR HPV includes infection with either type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 or 68
  3. P values for differences were not calculated for each specific HPV type between Māori and non-Māori women due to sample size limitations and concerns about multiple comparisons